220 related articles for article (PubMed ID: 28526367)
1. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
[TBL] [Abstract][Full Text] [Related]
3. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents.
Giordanetto F; Barlaam B; Berglund S; Edman K; Karlsson O; Lindberg J; Nylander S; Inghardt T
Bioorg Med Chem Lett; 2014 Aug; 24(16):3936-43. PubMed ID: 25042253
[TBL] [Abstract][Full Text] [Related]
5. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
6. Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.
Mortensen DS; Perrin-Ninkovic SM; Shevlin G; Zhao J; Packard G; Bahmanyar S; Correa M; Elsner J; Harris R; Lee BG; Papa P; Parnes JS; Riggs JR; Sapienza J; Tehrani L; Whitefield B; Apuy J; Bisonette RR; Gamez JC; Hickman M; Khambatta G; Leisten J; Peng SX; Richardson SJ; Cathers BE; Canan SS; Moghaddam MF; Raymon HK; Worland P; Narla RK; Fultz KE; Sankar S
J Med Chem; 2015 Jul; 58(13):5323-33. PubMed ID: 26083478
[TBL] [Abstract][Full Text] [Related]
7. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
[TBL] [Abstract][Full Text] [Related]
9. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Furet P; Guagnano V; Fairhurst RA; Imbach-Weese P; Bruce I; Knapp M; Fritsch C; Blasco F; Blanz J; Aichholz R; Hamon J; Fabbro D; Caravatti G
Bioorg Med Chem Lett; 2013 Jul; 23(13):3741-8. PubMed ID: 23726034
[TBL] [Abstract][Full Text] [Related]
10. Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
Martínez González S; Rodríguez-Arístegui S; Hernández AI; Varela C; González Cantalapiedra E; Álvarez RM; Rodríguez Hergueta A; Bischoff JR; Albarrán MI; Cebriá A; Cendón E; Cebrián D; Alfonso P; Pastor J
Bioorg Med Chem Lett; 2017 Jun; 27(11):2536-2543. PubMed ID: 28404374
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity.
Argyros O; Lougiakis N; Kouvari E; Papafotika A; Raptopoulou CP; Psycharis V; Christoforidis S; Pouli N; Marakos P; Tamvakopoulos C
Eur J Med Chem; 2017 Jan; 126():954-968. PubMed ID: 28006668
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
Barlaam B; Cosulich S; Degorce S; Fitzek M; Giordanetto F; Green S; Inghardt T; Hennequin L; Hancox U; Lambert-van der Brempt C; Morgentin R; Pass S; Plé P; Saleh T; Ward L
Bioorg Med Chem Lett; 2014 Aug; 24(16):3928-35. PubMed ID: 24992874
[TBL] [Abstract][Full Text] [Related]
14. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.
Nacht M; Qiao L; Sheets MP; St Martin T; Labenski M; Mazdiyasni H; Karp R; Zhu Z; Chaturvedi P; Bhavsar D; Niu D; Westlin W; Petter RC; Medikonda AP; Singh J
J Med Chem; 2013 Feb; 56(3):712-21. PubMed ID: 23360348
[TBL] [Abstract][Full Text] [Related]
17. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S
Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
19. 6,7-Dihydrobenzo[f]benzo[4,5]imidazo[1,2-d][1,4]oxazepine derivatives as selective inhibitors of PI3Kα.
Yin Y; Zhang YQ; Jin B; Sha S; Wu X; Sangani CB; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
Bioorg Med Chem; 2015 Mar; 23(6):1231-40. PubMed ID: 25693787
[TBL] [Abstract][Full Text] [Related]
20. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
Miller MS; Maheshwari S; McRobb FM; Kinzler KW; Amzel LM; Vogelstein B; Gabelli SB
Bioorg Med Chem; 2017 Feb; 25(4):1481-1486. PubMed ID: 28129991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
